Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Amplo Biotechnology is the developer of Adeno-Associated Viral (AAV) therapies designed to focus on cures for defects related to the neuromuscular junction. The company plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AMP-101 (AAV-Dok7), was developed by Professor Yuji Yamanash...
Amplo Biotechnology is the developer of Adeno-Associated Viral (AAV) therapies designed to focus on cures for defects related to the neuromuscular junction. The company plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AMP-101 (AAV-Dok7), was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo and is applicable to multiple rare, severe diseases.

List your booth number for exhibitions, ask us